Charles River Laboratories International, Inc. completed the acquisition of HemaCare Corporation.
Based on the anticipated closing date, the acquisition is expected to add at least $50 million to Charles River's 2020 consolidated revenue, with estimated revenue growth of at least 30% annually over the next five years. The transaction is expected to be neutral to non-GAAP earnings per share in 2020, and increasingly accretive thereafter. BofA Securities is acting as financial advisor to Charles River. Michael Davis, Kyoko Takahashi Lin, William A. Curran and David R. Bauer of Davis Polk & Wardwell LLP is acting as the legal advisor and Axinn, Veltrop & Harkrider LLP acted as the antitrust counsel to Charles River. Raal Leclerc and Ryan Plusch of Jefferies LLC acted as the financial advisor and Drew Altman and David Wells of Greenberg Traurig, LLP acted as legal advisors to HemaCare.
Charles River Laboratories International, Inc. (NYSE:CRL) completed the acquisition of HemaCare Corporation (OTCPK:HEMA) on January 3, 2020. Under the transaction, the HemaCare team will be joining the Charles River family.